8,328 Shares in Amgen Inc. $AMGN Purchased by Legato Capital Management LLC

Legato Capital Management LLC acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 8,328 shares of the medical research company’s stock, valued at approximately $2,726,000.

Other large investors have also bought and sold shares of the company. Brighton Jones LLC increased its position in shares of Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC lifted its position in Amgen by 10.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after acquiring an additional 114 shares in the last quarter. Schnieders Capital Management LLC. lifted its position in Amgen by 29.3% in the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock valued at $7,220,000 after acquiring an additional 5,853 shares in the last quarter. Main Street Financial Solutions LLC boosted its stake in Amgen by 11.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock valued at $1,141,000 after purchasing an additional 416 shares during the last quarter. Finally, Ieq Capital LLC boosted its stake in Amgen by 5.1% during the 2nd quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock valued at $15,120,000 after purchasing an additional 2,611 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.85% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen expanded its lung cancer pipeline by launching a phase 1b study testing a tarlatamab combination in small cell lung cancer, which could improve the company’s oncology growth prospects if the data are encouraging. Amgen Expands Lung Cancer Pipeline With New Tarlatamab Combo Study
• Positive Sentiment: Several reports highlighted Amgen as a long-term value/dividend and pipeline story, citing upside potential and analyst support such as an Overweight rating from Piper Sandler, reinforcing confidence in the company’s revenue growth outlook. Why Wall Street Thinks This Dividend Stock Could Jump 30%
• Positive Sentiment: Amgen shareholders reaffirmed the board, executive pay and auditors, which signals governance stability and removes a potential overhang. Amgen Shareholders Reaffirm Board, Pay and Auditors
• Neutral Sentiment: Amgen appointed Thomas Dittrich as chief financial officer, a management update that should be watched for any strategic or capital-allocation changes, but is not clearly a near-term stock catalyst. CFOs On the Move: Week ending May 22
• Negative Sentiment: Investor focus remains on safety concerns around Tavneos after reported patient deaths in Japan prompted restrictions on new prescriptions and raised the risk of withdrawal requests in the U.S., creating a potential earnings and sentiment headwind for Amgen. A Look At Amgen (AMGN) Valuation As Tavneos Safety Concerns And Withdrawal Requests Escalate
• Negative Sentiment: News that doctors in Japan could again prescribe Tavneos to new patients only partially eases concerns, because the drug still carries liver-injury warnings and the broader safety controversy may continue to pressure sentiment. Doctors in Japan can again prescribe an Amgen rare-disease drug to new patients, reversing a recommendation made only days ago following 20 deaths

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Wall Street Zen upgraded Amgen from a “hold” rating to a “buy” rating in a research note on Saturday. Deutsche Bank Aktiengesellschaft lifted their price objective on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a report on Thursday, February 5th. Morgan Stanley set a $332.00 target price on Amgen in a research report on Friday, May 1st. Mizuho upped their target price on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. Finally, Truist Financial raised their price target on shares of Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a report on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $355.19.

Amgen Stock Up 0.6%

AMGN stock opened at $339.30 on Friday. The company has a market cap of $183.12 billion, a price-to-earnings ratio of 23.61, a P/E/G ratio of 3.39 and a beta of 0.44. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The business’s 50-day moving average is $345.10 and its two-hundred day moving average is $344.38. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same period in the previous year, the company posted $4.90 EPS. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts forecast that Amgen Inc. will post 22.37 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is currently 70.15%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.